Assurex Health to Present New Research on GeneSight Combinatorial Pharmacogenomic (CPGx™) Test Cost Savings at the American Psychiatric Association Annual Meeting
MASON, OH — May 16, 2015 – Assurex Health will share new research and participate in a full schedule of activities at the American Psychiatric Association 168th Annual Meeting in Toronto from May 16th through May 20th.
Promising Research on CPGx Testing
Assurex Health will present a new research poster session titled “Health Care Utilization and Medication Cost Savings in Patients Receiving Psychiatric Combinatorial Pharmacogenomic Testing” on Tuesday, May 19th from 2 pm – 4 pm. An analysis of data from Medco and Union Health Services shows that by using the GeneSight Psychotropic pharmacogenomic test compared with the current standard of care, an average of $1,036 in prescriptions and $1,556 in healthcare service utilization can be saved for a total of savings of $2,592 annually.
The presentation will be in Exhibit Hall D-E at the Toronto Convention Centre, South, Level 800.
GeneSight is the only neuropsychiatric combinatorial pharmacogenomic (CPGxTM) test covered by Medicare and the U.S. Department of Veterans Affairs, and proven in multiple peer-reviewed, published clinical studies to enhance medication selection. It analyzes how an individual’s genetic variations affect his or her individual response to medications and provides an actionable, easy to interpret report for healthcare providers to help them get their patients on the right medications faster.
Product Theater, Booth Also Scheduled
Assurex Health will be hosting a one hour Product Theater entitled “Next Generation Pharmacogenomics: Moving Beyond Mendel” on Tuesday, May 19th at noon in the APA Exhibit Hall. The product theater, for up to 300 attendees, will feature Christopher Bojrab, MD. Dr. Bojrab is a board certified psychiatrist and president of Indiana Health Group. He is Distinguished Fellow of the American Psychiatric Association who treats child, adolescent, adult, and geriatric patients. His areas of interest include psychopharmacology, mood and anxiety disorders, ADHD, sleep disorders, pain syndromes, and gambling addiction. In addition to clinical practice, he maintains a busy lecture schedule delivering over 100 presentations, teleconferences, and CME seminars internationally each year.
In addition, Assurex Health will be showcasing GeneSight and a new peer-reviewed study published in The Pharmacogenomics Journal in Booth #939. The research team, led by C. Anthony Altar, Ph.D., Assurex Health Senior Vice President of Neurosciences, demonstrated the superiority of the CPGx method of the GeneSight test, and how this method contributes to it being the most effective test available to guide healthcare professionals in making treatment decisions for behavioral health conditions.
Exhibit hours are 10:00 am – 4:00 pm on Sunday, May 17th through Tuesday, May 19th.
GeneSight helps healthcare providers make more precise treatment decisions based on how a patient’s unique genetic makeup affects their individual response to 38 FDA-approved medications for depression, anxiety, posttraumatic stress disorder (PTSD), bipolar disorder, schizophrenia and other mental health conditions. GeneSight is the only neuropsychiatric combinatorial pharmacogenomic test validated in multiple, peer-reviewed, published clinical studies. GeneSight analyzes over 785,000 permutations of an individual’s genes and available medications, and presents the results in an easy to read, color-coded report available typically within 36 hours after Assurex Health receives a patient’s cheek swab. Many commercial and government insurance plans, including Medicare and the U.S. Department of Veterans Affairs, reimburse all or part of the cost of GeneSight. Assurex Health also offers financial assistance programs for patients who qualify. Learn more at www.genesight.com.
About Assurex Health
Assurex Health is a commercial-stage, informatics-based precision medicine company providing treatment decision support to healthcare providers for behavioral health conditions. Assurex Health’s proprietary GeneSight technology is based on combinatorial pharmacogenomics (CPGx™) – the application of multiple genetic factors that influence an individual’s response to medications – as well as evidence-based medicine and clinical pharmacology. Assurex Health has licensed patented technology from Mayo Clinic and Cincinnati Children’s Hospital Medical Center, both of whom continue to be research collaborators. Learn more at www.assurexhealth.com.